Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma

This review has been withdrawn.

The reason for withdrawal and previous versions are archived and accessible within the withdrawn record in the Cochrane Library.

Health topics:

Published:

30 October 2016

Authors:

Kharfan-Dabaja M, Nishihori T, Reljic T, Hamadani M, Baz R, Ochoa-Bayona JL., Mhaskar R, Djulbegovic B, Kumar A

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Kharfan-Dabaja M, Nishihori T, Reljic T, Hamadani M, Baz R, Ochoa-Bayona JL., Mhaskar R, Djulbegovic B, Kumar A. Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma. Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No.: CD010602. DOI: 10.1002/14651858.CD010602.pub2